HC Reform Update from Mark Sanna: A federal advisory panel on Thursday voted narrowly to recommend allowing Eli Lilly to market its antidepressant, Cymbalta, for some chronic pain conditions affecting millions of Americans, particularly lower back pain. The scientific advisory panel to the FDA voted 8 to 6 in favor of expanding approved uses of Cymbalta.